Compare HYT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HYT | PHAR |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | HYT | PHAR |
|---|---|---|
| Price | $8.48 | $12.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 738.4K | 10.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $9.54 |
| 52 Week High | $9.88 | $21.34 |
| Indicator | HYT | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 32.76 |
| Support Level | $8.22 | $11.43 |
| Resistance Level | $8.70 | $13.44 |
| Average True Range (ATR) | 0.06 | 0.50 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 31.25 | 20.11 |
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide shareholders with current income. The trust's secondary investment objective is to provide shareholders with capital appreciation. Under Normal market conditions, the fund invests at least 80% of its net assets in high-yield securities of corporate issuers and derivatives that provide exposure to those securities or related market risk factors.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.